---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013100"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:54:32.872595+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve SKNY acquisition; combined enterprise value >$60M

## Summary
- SKNY will contribute $5M in cash or assets to MIRA at closing.
- Moore Financial Consulting valued SKNY at $30.5M and MIRA at $30M; combined >$60M.
- Directors elected: Erez Aminov, Matthew Whalen, Matthew Del Giudice, Denil Nanji Shekhat, Edward MacPherson.
- 2022 Omnibus Incentive Plan amended: shares increased from 5M to 8M, option repricing allowed.
- Transaction expected to close shortly, subject to customary closing conditions.

## SEC filing metadata
- accession: 0001493152-25-013100
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315225013100/0001493152-25-013100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315225013100/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013100
- JSON: https://secwatch.observer/filing/0001493152-25-013100.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.